Download the full-sized PDF of Metalloproteinases in the Development of Hypertension and Cardiac RemodelingDownload the full-sized PDF



Permanent link (DOI):


Export to: EndNote  |  Zotero  |  Mendeley


This file is in the following communities:

Graduate Studies and Research, Faculty of


This file is in the following collections:

Theses and Dissertations

Metalloproteinases in the Development of Hypertension and Cardiac Remodeling Open Access


Other title
cardaic fibrosis
cardiac hypertrophy
Type of item
Degree grantor
University of Alberta
Author or creator
Wang, Xiang
Supervisor and department
Fernandez-Patron, Carlos (Biochemistry)
Examining committee member and department
MacDonald, Justin (Biochemistry & Molecular Biology, Universtiy of Calgary)
Stone, James (Biochemistry)
Schang, Luis (Biochemistry)
Sipione,Simonetta (Pharmacology)
Kassiri, Zamaneh (Physiology)
Department of Biochemistry

Date accepted
Graduation date
Doctor of Philosophy
Degree level
Despite many decades of research and drug development, the diseases of the cardiovascular system remain a major health threat in the modern world. Hypertensive cardiac disease is a cardiovascular condition characterized by the co-occurrence of hypertension and pathological cardiac remodeling (hypertrophy and fibrosis). Causative factors of hypertensive cardiac disease range from environmental stress to metabolic morbidities. However, these detrimental factors have a common effector mechanism: the sustained activation of G protein-coupled receptors (GPCRs) due to pathological levels of cognate agonists which elevate systemic blood pressure and promote pathological cardiovascular remodeling. GPCR agonists can trigger the activation of metalloproteinases, including matrix metalloproteinases (MMPs) and a disintegrin and metalloproteinases (ADAMs). These metalloproteinases are multifunctional enzymes that transactivate many intracellular signaling pathways including those leading to hypertension and cardiac remodeling. Therefore, MMPs and ADAMs have been widely speculated to be potential treatment targets for hypertensive cardiac disease. In the current studies, we use angiotensin II and adrenoceptor ligands as prototypes of GPCR agonists to gain insights into mechanisms of hypertensive heart disease in rodent models. We determine various new roles played by MMP-2, MMP-7, ADAM-12 and ADAM-17. We demonstrate that: 1. MMP-7 mediates GPCR agonist-induced signaling with MMP-7 inhibition by pharmacological blockade, RNA interference or genetic knockout protecting against hypertensive cardiac remodeling. 2. ADAM-17 also contributes to GPCR agonist-induced cardiac hypertrophy and fibrosis. These effects of ADAM-17 are signaledby ADAM-12, a major effector metalloproteinase in cardiac hypertrophy signaling. 3. MMP-2 contributes to the development of GPCR agonist-induced hypertension such that partial blockade of MMP-2 by inhibitors and RNA interference attenuates angiotensin II-induced hypertension. 4. MMP-2 protects against hypertensive cardiac remodeling. To explain the cardioprotection rendered by MMP-2, we evoke a novel mechanism of negative regulation of the sterol-regulatory element binding protein (SREBP)-2 / 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR) pathway of cardiac remodeling. These findings are a major contribution to our current understanding of the cardiovascular biology of metalloproteinases. Our data show the diverse roles of metalloproteinases in hypertensive cardiac disease and the potential and limitations of therapeutic approaches based on metalloproteinase inhibition for management of cardiovascular disease.
Permission is hereby granted to the University of Alberta Libraries to reproduce single copies of this thesis and to lend or sell such copies for private, scholarly or scientific research purposes only. Where the thesis is converted to, or otherwise made available in digital form, the University of Alberta will advise potential users of the thesis of these terms. The author reserves all other publication and other rights in association with the copyright in the thesis and, except as herein before provided, neither the thesis nor any substantial portion thereof may be printed or otherwise reproduced in any material form whatsoever without the author's prior written permission.
Citation for previous publication
Wang X, Chow FL, Oka T, Hao L, Lopez-Campistrous A, Kelly S, Cooper S, Odenbach J, Finegan B, Schulz R, Kassiri Z, Lopaschuk G, Fernandez-Patron C. MMP-7 and ADAM-12 define a signaling axis in agonist-induced hypertension and cardiac hypertrophy. Circulation. 2009 May 12;119(18):2480-9Wang X, Oka T, Chow FL, Cooper S, Odenbach J, Lopaschuk G, Kassiri Z, Fernandez-Patron C. TACE is a key regulator of agonist-induced cardiac hypertrophy. Hypertension. 2009 Sep;54(3):575-82.Odenbach J, Wang X, Cooper S, Chow FL, Oka T, Lopaschuk G, Kassiri Z, Fernandez-Patron C. MMP-2 mediates angiotensin II-induced hypertension under the transcriptional control of MMP-7 and TACE. Hypertension. 2011 Jan;57(1):123-30.

File Details

Date Uploaded
Date Modified
Audit Status
Audits have not yet been run on this file.
File format: pdf (Portable Document Format)
Mime type: application/pdf
File size: 7664834
Last modified: 2015:10:12 17:03:00-06:00
Filename: Wang_Xiang_Fall 2013.pdf
Original checksum: 1aa4549d50bdf59f6a24383324e840e8
Well formed: true
Valid: true
Status message: Too many fonts to report; some fonts omitted. Total fonts = 1045
File title: Chapter 1 introduction
File author: gfore
Page count: 339
File language: en-CA
Activity of users you follow
User Activity Date